INTERNATIONAL PATENT: QURALIS CORPORATION FILES APPLICATION FOR "TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS"

GENEVA, April 20 -- QURALIS CORPORATION (100 Cambridgepark DriveSuite 500Cambridge, Massachusetts 02140) filed a patent application (PCT/US2025/049415) for "TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS" on Oct 03, 2025. With publication no. WO/2026/080323, the details related to the patent application was published on Apr 16, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ELBAUM, Daniel (c/o Eli Lilly and CompanyP.O. Box 6288Indianapolis, Indiana 46206-6288), KAMELGARN, Marisa Elizabeth (c/o Eli Lilly and CompanyP.O. Box 6288Indianapolis, Indiana 46206-6288...